Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
semdexa
- Development stage
- Phase 3
- Lead developer
- Scilex Holding
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Administration
- Epidural
01
Overview
Semdexa (SP-102) is a novel injectable corticosteroid gel formulation of dexamethasone sodium phosphate, developed for the treatment of moderate to severe lumbosacral radicular pain, commonly known as sciatica. It is administered epidurally and is preservative-free, surfactant-free, suspension-free, and particulate-free. Semdexa provides rapid onset of pain relief with effects lasting up to 99 days following a single injection. The drug has demonstrated statistically significant and clinically meaningful improvements in pain intensity and disability index scores in clinical trials[2][5][6].
- Brand names
- SEMDEXA™Semdexa
- Other names
- SP-102 (SEMDEXA™)
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on semdexa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on semdexa.